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Abstract
Background Beta-blocker (BB) therapy after myocardial
infarction (MI) reduces all-cause mortality.
Objective The aim of this study was to investigate BB
dosing patterns and compliance following MI.
Methods Using medical patient files and nationwide data-
bases, we identified 100 patients who were discharged fol-
lowing MI in 2012 from Aarhus University Hospital,
Denmark, and subsequently redeemed one or more BB pre-
scriptions within 6 months. We obtained information about
all BB medication prescribed at discharge and all BB pre-
scriptions redeemed until 31 December 2013. Daily BB doses
were computed as percentages of the target doses used in
clinical trials documenting the efficacy of BBs after MI. Four
dose groups were defined: B12.5, [12.5–25, [25–50, and
[50 % of target dose. The proportion of patients in each dose
group was ascertained at and following discharge, as was the
proportion that changed dose group following discharge.
Results The median study period was 400 days (in-
terquartile range [IQR] 318–486 days). At discharge, 8 %
of daily doses were[50 % of target dose while 80 %
were B25 % of target dose. At first prescription redemp-
tion, 71.7 % of patients moved to a higher dose group
(median dose change = 33.4 % [IQR 2.0–115.1]). Still,
comparing final daily doses to discharge doses, 40.2 % did
not change dose group (median dose change -5.7 % [IQR
-18.0 to 4.2]). Only 31.5 % reached a final daily dose
[50 % of target dose.
Conclusions Target dose BB treatment was infrequently
achieved at discharge following MI. Despite dose up-titration
early after discharge, most patients did not receive target dose
BB treatment approximately 1 year following MI.
Key Points
Even though the beneficial effect of beta-blockers
was discovered several decades ago, target dose
beta-blocker treatment is still infrequently achieved
at discharge following myocardial infarction.
Based on redeemed prescriptions rather than self-
reported beta-blocker use, this study showed that
most patients do not receive target dose beta-blocker
treatment approximately 1 year following
myocardial infarction.
As beta-blocker dose may affect outcome, our
findings emphasize the importance of tracking beta-
blocker use following myocardial infarction to
properly assess the impact of treatment and dose on
survival.
1 Introduction
Beta-blocker (BB) therapy after myocardial infarction
(MI) reduces all-cause mortality [1–3] and is recom-
mended by international guidelines in the absence of
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contraindications [4, 5]. Evidence from randomized clin-
ical trials indicate that the target doses of frequently used
BBs are metoprolol 200 mg/day [6], carvedilol 50 mg/day
[7], bisoprolol 10 mg/day [8], atenolol 100 mg/day [9],
and propranolol 180 mg/day [10]. Still, BB doses pre-
scribed for patients after MI are often considerably lower
[11, 12]. Although treatment with doses lower than those
used in the randomized clinical trials that established their
efficacy might be expected to be associated with poorer
outcomes, the PACE-MI (Pacemaker and beta-blocker
therapy post-MI) Registry Study—OBTAIN (Outcomes
of Beta-blocker Therapy After Myocardial Infarction)
recently demonstrated that treatment with target doses
was not superior to treatment with 25 % of the target dose
[13]. As this is the only available large-scale study to
evaluate the effect of BB dose on outcome, further efforts
to assess the BB dose-dependency on outcome after MI
are required. Large healthcare system databases can be
useful to address this question, but are often limited to
discharge medication doses. Discharge BB doses may not
reflect actual doses taken by patients during follow-up
because the prescription was never redeemed or the dose
was changed. Non-adherence to prescribed cardiovascular
medication is a well known occurrence among post-MI
patients, encompassing failure to take the medication as
prescribed and failure to take the medication at all
[14, 15]. Thus, some post-MI patients may take BB doses
that differ from doses prescribed at discharge. Most pre-
vious studies of BB use early after MI relied on prescribed
medication or patient recollection of administered medi-
cation [11–14], which carries a risk of recall bias. The aim
of our study was to compare BB medication prescribed at
discharge after MI with subsequent pharmacy-dispensed
BB medication, thereby eliminating recall bias. Assuming
that pharmacy redemptions are only performed when
patients need additional medication, this provides the
most accurate assessment of the actual BB consumption
for an individual patient.
2 Methods
2.1 Design and Setting
This observational study was conducted in Denmark
where healthcare is tax-funded, guaranteeing all
inhabitants access to general practitioners and hospitals
[16], and providing partial reimbursement of most
prescription medication expenses [17]. Each Danish
inhabitant has a unique civil registration number, which
is a prerequisite for receiving health care and allows for
accurate and unambiguous linkage of national registries
[16].
2.2 The Danish National Patient Registry
The Danish National Patient Registry (DNPR) maintains
records of all hospitalizations in Denmark since 1977 [18].
Upon hospital discharge, the treating physician records a
primary diagnosis describing the main reason for diag-
nostic work-up and treatment, and up to 19 secondary
diagnoses describing comorbid conditions [18]. Diagnoses
are coded according to the World Health Organization’s
International Classification of Diseases, 8th revision until
the end of 1993 and 10th revision (ICD-10) thereafter. The
treating physician also records discharge medication in the
patient’s electronic medical file and a copy is given to the
patient and sent to his or her general practitioner.
2.3 The Danish National Database of Reimbursed
Prescriptions
Danish pharmacies are required by law to register all pre-
scriptions redeemed and BBs are prescription-only medi-
cation in Denmark. Electronic records of prescriptions
redeemed since 2004 are kept in the Danish National
Database of Reimbursed Prescriptions (NDP) [17]. A bar-
code identifier on each medication package enables auto-
matic registration of information about the dispensed
medication, including Anatomical Therapeutic Chemical
(ATC) code, strength, pack size, pack quantity, and date of
redemption. Information about the person redeeming the
prescription, including civil registration number, is also
registered.
2.4 The Danish Civil Registration System
All changes in vital status have been registered in the
Danish Civil Registration System since 1968, with daily
electronic updates [16]. Information about vital status is
transferred from the Danish Civil Registration System to
electronic medical patient files on a daily basis.
2.5 Myocardial Infarction Patients
Using primary and secondary in-patient hospital discharge
diagnosis codes recorded in the DNPR, we identified
patients who were hospitalized with MI in 2012 (ICD-10
code I21) without an antecedent MI diagnosis during
2006–2011. Eligible patients were discharged to their home
from the Department of Cardiology, Aarhus University
Hospital, Denmark, with BB treatment and redeemed one
or more BB prescriptions within 6 months following hos-
pital admission. Being highly specialized, the Department
of Cardiology at Aarhus University Hospital treats cardiac
patients admitted from home or transferred from other less
specialized departments in the Central Denmark Region.
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Among 192 eligible patients, 100 were randomly selected
and included in the study. Medical patient files were
reviewed twice by one reviewer (SBP) to obtain informa-
tion on gender, age, type and daily dose of BBs at dis-
charge, and co-medication at discharge; that is, aspirin,
statins, angiotensin-converting enzyme (ACE) inhibitors or
angiotensin receptor blockers (ARBs), ticagrelor, clopido-
grel, anticoagulants, and medications for diabetes mellitus.
Using the NDP, we categorized patients as ‘prior users’ if
they had redeemed one or more BB prescriptions prior to
MI hospitalization. Information about vital status was also
obtained by review of the electronic medical patient files
(SBP).
2.6 Beta-Blockers
Information on all prescriptions for metoprolol, carvedilol,
bisoprolol, atenolol, and propranolol redeemed during
2004–2013 was obtained for each patient from the NDP.
Prescriptions redeemed on the same date were counted as
one prescription. Because daily doses are not recorded
directly in the NDP, they were computed for patients who
redeemed two or more prescriptions as the content of each
prescription (i.e., strength 9 pack size 9 pack quantity)
divided by the number of days to the following prescription
redemption [19]. A new daily dose was computed every
time a prescription was redeemed. The daily dose was
assumed to be constant between two prescription redemp-
tions. The final daily dose in the study period was com-
puted as the content of the before-last prescription
redeemed, divided by the number of days between the
before-last and the last prescription redeemed. No daily
dose could be calculated for patients who redeemed only
one prescription after discharge. When a patient changed
BB type during follow-up, the last daily dose before the BB
change was discarded and daily doses were not computed
after a change of BB. Daily BB doses were recalculated to
percentages of target dose; that is, daily BB dose/BB target
dose. We defined four dose groups: B12.5 % of target dose,
[12.5–25 % of target dose,[25–50 % of target dose, and
[50 % of target dose [13]. Dose calculations and ATC
codes are provided in Table S1 in the electronic supple-
mentary material.
2.7 Statistical Analysis
We categorized patients at discharge according to gender, age
(\65 years, 65–75 years, or[75 years), BB type (metopro-
lol, carvedilol, bisoprolol, atenolol, or propranolol), BB dose
group, and co-medication, overall and for prior users and new
users, respectively. Median duration of hospitalization and
age at discharge were computed with interquartile ranges
(IQRs). We ascertained the total number of prescriptions
redeemed during follow-up and the median number of pre-
scriptions redeemed per patient. The median time from dis-
charge to prescription redemption was computed.
The number of patients in each BB dose group at dis-
charge and during the study period was ascertained. Each
patient’s final daily dose was compared with the dose at
discharge and the proportion of patients who remained in
the same BB dose group, or moved to a higher or lower
dose group, respectively, was computed. To assess inter-
dose variability during the study period, the difference
between each daily dose and the preceding daily dose was
computed, and the median variability for all patients was
derived. The first daily dose was compared with the dose at
discharge. The proportion of patients who changed BB
dose group (any change, increase, or decrease) was ascer-
tained at each prescription redemption.
3 Results
3.1 Patient Demographics and Medication
at Discharge
We reviewed 106 eligible patient files. Six of them were
excluded due to ambiguous BB discharge doses in the
medical files. Included patients had a median hospitalization
duration of 3 days (IQR 2–4). Table 1 shows demographics
and medication at discharge. Median age at discharge was
70 years (IQR 60–78) for all patients, 67 years (IQR 55–76)
for new users, and 74 years (IQR 64–79) for prior users. The
majority of patients were discharged with metoprolol
(Table 1). The median daily dose at discharge was 25.0 %
(IQR 25.0–25.0) of target dose for all patients, 25.0 %
(12.5–25.0) for new users and 25.0 % (IQR 25.0–50.0) for
prior users. The median daily dose at discharge did not differ
between men (25.0 % [IQR 25.0–25.0] of target dose) and
women (25.0 % [IQR 12.5–37.5] of target dose). Only 8 %
of all patients were discharged with a daily BB dose[50 %
of target dose, new users almost ten times less often than
prior users, and 80 % of patients were discharged with a
daily BB dose B25 % of target dose. Co-medication with
statins and ticagrelor was more frequent among new users,
while ACE inhibitors/ARBs and clopidogrel were more
frequent among prior users.
3.2 Prescription Redemptions
A total of 688 prescriptions were redeemed during a
median study period (i.e. time from discharge to last pre-
scription redemption) of 400 days (IQR 318–486). The
median number of prescriptions redeemed during the study
period was 6 (IQR 4–8) per patient. Four patients changed
BB type during the study period.
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Figure 1 illustrates time from discharge to prescription
redemption. The median time from discharge to first pre-
scription redemption was 2 days (IQR 1–4), longer for
prior users (8 days [IQR 2–58]) than for new users (1 day
[IQR 0–2]). Overall, the median time between prescription
redemptions was 52 days (IQR 27–94) and the median time
from discharge to the before-last prescription redemption,
used for calculation of the final daily dose, was 321 days
(IQR 227–391). Seven patients, among them five new
users, redeemed only one prescription after discharge
(median discharge dose = 12.5 % of target dose [IQR
12.5–18.8]).
3.3 Beta-Blocker Dose after Discharge
Figure 2 illustrates the distribution of patients in each of
the four BB dose groups at and following discharge. While
the number of patients with a daily dose B25 % of target
dose decreased from 80 at discharge to 16 at first pre-
scription redemption, the number of patients with a daily
dose[50 % of target dose increased from 8 to 34. Still,
only 31.5 % (n = 29) of patients had a final daily
dose[50 % of target dose; that is, 19.0 % (n = 11) of new
users and 42.9 % (n = 18) of prior users. The median final
daily dose was 28.6 % (IQR 22.2–66.1) of target dose,
ranging from 24.3 % (IQR 19.4–46.7) for new users to
43.1 % (IQR 26.2–101.1) for prior users. Comparing the
final daily dose with the dose at discharge, 40.2 % (n = 37
[24 new users and 13 prior users]) remained in the same
dose group (median dose change -5.7 % [IQR -18.0 to
4.2]), while 50.0 % (n = 46 [23 new users and 23 prior
users]) moved to a higher dose group (median dose
increase 89.6 % [IQR 28.6–319.5]) and 9.8 % (n = 9 [6
new users and 3 prior users]) moved to a lower dose group
(median dose decrease -51.5 % [IQR-57.1 to -50.2]).
3.4 Death During Follow-Up
Two of the seven patients who redeemed only one pre-
scription after discharge died during the study period, 13
and 41 days after prescription redemption, respectively.
Both patients were men of at least 80 years and prior users.
Table 1 Patient demographics
and medications at discharge
after myocardial infarction
All patients, n (%)
N = 100
New users, n (%)
N = 58
Prior users, n (%)
N = 42
Gender
Male 76 (76.0) 45 (77.6) 31 (73.8)
Female 24 (24.0) 13 (22.4) 11 (26.2)
Age, years
\65 34 (34.0) 23 (39.7) 11 (26.2)
65–75 31 (31.0) 18 (31.0) 13 (31.0)
[75 35 (35.0) 17 (29.3) 18 (42.9)
BB type
Metoprolol 84 (84.0) 48 (82.8) 36 (85.7)
Carvedilol 11 (11.0) 9 (15.5) 2 (4.8)
Bisoprolol 4 (4.0) 1 (1.7) 3 (7.1)
Atenolol 1 (1.0) 0 (0.0) 1 (2.4)
Propranolol 0 (0.0) 0 (0.0) 0 (0.0)
BB dose group, %
B12.5 21 (21.0) 16 (27.6) 5 (11.9)
[12.5–25.0 59 (59.0) 38 (65.5) 21 (50.0)
[25.0–50.0 12 (12.0) 3 (5.2) 9 (21.4)
[50.0 8 (8.0) 1 (1.7) 7 (16.7)
Co-medication
Aspirin 98 (98.0) 58 (100.0) 40 (95.2)
Statin 85 (85.0) 52 (89.7) 33 (78.6)
ACE-inhibitor/ARB 50 (50.0) 25 (43.1) 25 (59.5)
Ticagrelor 66 (66.0) 43 (74.1) 23 (54.8)
Clopidogrel 27 (27.0) 10 (17.2) 17 (40.5)
Anticoagulant 8 (8.0) 2 (3.4) 6 (14.3)
Diabetes medication 8 (8.0) 6 (10.3) 2 (4.8)
ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, BB beta-blocker
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They were discharged with metoprolol 25 mg daily. As
they only redeemed one prescription after discharge, no
daily dose could be computed, but both patients picked up
BB pills with the same strength (metoprolol 25 mg) as at
their last prescription redemption before admission for MI.
Another five patients with at least two BB prescription
redemptions after discharge died during follow-up,
between 227 and 400 days following discharge. Their age
Fig. 1 Time from discharge to
prescription redemption. Boxes
illustrate medians with upper
and lower quartiles. Whiskers
illustrate maximum and
minimum
Fig. 2 Distribution of patients
in beta-blocker dose groups
according to prescription
number. Prescription no. 0
corresponds to discharge
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ranged from 70.8 to 90.1 years, three were women, and one
was a prior user. All had redeemed three or more BB
prescriptions after discharge. The latest computed daily
dose was B12.5 % of target dose for one patient,
12.5–25 % of target dose for two patients, and[50 % of
target dose for two patients. No daily dose could be com-
puted after the last prescription redemption, but all five
patients picked up BB pills with the same strength in mg as
at the preceding prescription redemption, and four of the
five also picked up the same number of pills as at the
preceding prescription redemption. Of the 93 patients alive
at the end of 2013, 26 (28.0 %) had not redeemed a BB
prescription within the last 100 days.
3.5 Inter-Dose Variability
Figure 3 illustrates inter-dose variability during the study
period. The largest dose change was observed when the
first daily dose was compared with the dose at discharge.
Comparing subsequent daily doses, there was less inter-
dose variability as most median changes ranged within
±10 %. Among prior users, daily doses fluctuated less than
among new users (Figure S1 in the electronic supplemen-
tary material). From discharge to the final daily dose, we
observed a median dose change of 11.1 % (IQR -10.1 to
94.2), ranging from 6.4 % (IQR -13.8 to 88.7) among new
users to 11.1 % (IQR -1.0 to 142.0) among prior users.
More than 70 % of patients in our study changed BB dose
group at first prescription redemption, particularly new users
(Fig. 4a). The proportion of patients who changed BB dose
group generally decreased with increasing prescription num-
ber (Fig. 4a). While the proportion of patients who moved to
a higher BB dose group was larger at first prescription
redemption than at subsequent redemptions (Fig. 4b), the
proportion that moved to a lower BB dose group was largest
at second prescription redemption (Fig. 4c).
4 Discussion
4.1 Main Findings
We found that only 8 % of MI patients discharged from
hospital with a BB were prescribed a daily dose[50 % of
the target dose, while 80 % were prescribed a daily
dose B25 % of the target dose. Although a considerable
dose up-titration followed early after discharge, 40 % of
patients remained in the same BB dose group when the
final daily dose was compared with the dose at discharge,
and only 31.5 % had a final daily dose[50 % of target
dose. There was substantial attrition in BB prescription
redemption (and presumably use) so that 28.0 % of patients
alive by the end of the study period had not redeemed a BB
prescription within the last 100 days.
4.2 Discharge Dosing
To our knowledge, this is the first study of BB dosing
patterns at and following discharge after MI in Denmark.
Our results are in agreement with findings from other
Fig. 3 Dose variability during
the study period for all patients,
comparing each daily dose to
the preceding daily dose. The
first daily dose was compared
with the dose at discharge
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Fig. 4 Proportion of patients
with any change (a), increase
(b), or decrease (c) in BB dose
group according to number of
redeemed prescriptions. BB
beta-blocker
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countries that have reported discharge doses[50 % of
target doses among 13–60 % of post-MI patients [11–13].
These findings suggest that there is a widespread prefer-
ence to use BBs at doses substantially below the target
doses used in the clinical trials that established their effi-
cacy. This practice has little supporting data except for the
recently reported OBTAIN study [13].
4.3 Dose Up-Titration and Achievement of Target
Dose
More than 70 % of patients in our study changed BB dose
group at first prescription redemption. In comparison, only
23.5 % of post-MI patients treated with BBs in a US study
had a dose change within 3 weeks of discharge [11]. This
international difference may in part reflect that only 8 % of
patients in our study were discharged with daily BB
doses[50 % of target dose, as opposed to 17 % in the US
study, causing physician propensity to up-titrate BB treat-
ment among patients in our study to be higher. Further-
more, international differences in medication payment
regulations, post-MI rehabilitation, and early follow-up
may have played a role, as medical expenses [14, 15],
participation in rehabilitation [20], and early follow-up [21]
affect medication adherence.
Despite early dose up-titration, only 31.5 % had a final
daily BB dose[50 % of target dose. This finding is in line
with that of Arnold et al., who reported that approximately
28 % of 6748 MI patients had BB doses[50 % of target
doses at 1-year follow-up [12]. Although our estimate may
not be entirely comparable to these findings because final
daily doses in our study were not necessarily achieved at
1-year follow-up, both studies indicate that the majority of
MI patients do not achieve BB target dose approximately
1 year after discharge. Based on the high numbers of
patients achieving BB target doses in clinical trials [11], it
seems unlikely that BB intolerance prevented dose up-ti-
tration in all cases of under-dosing in our study.
4.4 Treatment Discontinuation
An important finding in our study was that 28.0 % of
patients alive at the end of the study period had not
redeemed a BB prescription within the last 100 days and
therefore likely disrupted BB treatment. This finding sup-
ports that of a US study in which approximately 30 % of
post-MI patients were not taking any BB at 12-month fol-
low-up [12]. This is a significant clinical issue given the
heavy evidence favoring any BB dose over no BB dose
treatment following MI. We cannot know whether the seven
patients who died during follow-up in our study had stopped
taking BB. However, they all picked up the same or a larger
amount of BB at their last prescription redemption as at the
preceding prescription redemption, which may indicate
continued use of the same or a higher daily dose.
4.5 Dose Variability
Although 40 % had not changed BB dose group when the
final daily dose was compared with the dose at discharge, a
Fig. 4 continued
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considerable proportion of patients changed BB dose group
during the study period. This could reflect the use of
arbitrary cut-off points to define BB dose groups, as even a
small dose change could have caused movement to another
BB dose group. Furthermore, some inter-dose variability is
likely an artifact of the variability in time of filling pre-
scription renewals. In a study of 55,315 Danish MI
patients, Gislason et al. found that average daily BB doses
1–5 years after MI changed only 4–7 % compared with
average doses of the first year after MI [19]. However, the
authors did not include discharge doses and dose variability
within the first year of discharge after MI. Our study pro-
vides new information about BB dosing at discharge and
dose variability early after MI in Denmark.
4.6 Study Strengths and Limitations
The major advantages of this study lie in the completeness
and accuracy of the nationwide prescription data used [17]
and in the high validity of the MI diagnosis in the DNPR
[22]. By using prescription data rather than questionnaires
or medical patient files, we avoided recall bias and bias
from primary non-adherence (i.e., failure to redeem pre-
scriptions) [15]. Although we cannot completely exclude
confounding from secondary non-adherence (i.e., failure to
take the obtained medication [15]), the assumption remains
reasonable that patients fill the prescription only when they
need additional medication, indicating completion of the
prior prescription. Thus, prescription data represent the
best available estimate of actual BB medication use rather
than intended use based on the prescribed dose. However,
it should be noted that the daily doses derived from NDP
data serve only as an approximation of the real dose as
patients may not always redeem a new prescription on the
day they run out of medication. A longer follow-up period
would have strengthened our study. However, clinical trials
have demonstrated that both short- and long-term BB
treatment following MI reduce mortality significantly [1].
Finally, due to its purely descriptive design, no sample size
calculation was performed for this study and the sample
size was limited by the need for review of individual
medical patient files. Thus, it was not possible to include all
MI patients in Denmark and our data represent the BB use
pattern from only one hospital in Denmark. Conceivable
regional and global variations require further examination.
5 Conclusions
We found that BB treatment infrequently achieves target
dose at discharge after MI. Despite dose up-titration early
after discharge, most patients did not receive BB treatment
in target dose approximately 1 year after MI. As dose may
affect outcome [13], our findings provide important quality
metrics and emphasize the importance of tracking BB use
following MI to properly assess the impact of treatment
and dose on survival.
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